DBV Technologies S.A. ADR Company Profile
NASDAQ: DBVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
DBV Technologies S.A. at a glance
DBV Technologies S.A. ADR (NASDAQ: DBVT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Châtillon, France. DBV Technologies S.A. is led by Mr. Daniel Tassé and employs about 179 people. The company's shares have traded publicly since 2014.
At a market capitalization of $566.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001613780, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does DBV Technologies S.A. do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Business description based on the company's public filings.
Company information
- Legal name
- DBV Technologies S.A. ADR
- Ticker
- NASDAQ: DBVT
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Daniel Tassé
- Employees
- 179
- Headquarters
- BAtiment IRO, Châtillon, France
- Phone
- 33 1 55 42 78 78
- Website
- dbv-technologies.com
- IPO year
- 2014
- Market cap
- $566.82M
- SEC CIK
- 0001613780
- Latest annual report
- 10-K/A · Apr 30, 2026
Companies similar to DBV Technologies S.A.
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs DBVT |
| FDMT4D Molecular Therapeutics Inc. | 10.23 | -4.57% | $576.76M | vs DBVT |
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs DBVT |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs DBVT |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs DBVT |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs DBVT |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs DBVT |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs DBVT |